30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Connecticut has joined the growing number of states passing or enhancing laws aimed to deter sexual ...
Read More >
In today’s edition of Daily Compliance News: Mark Zuckerberg really does want to crush competition...
Read More >
A Time of Change - We are in a period of immense change in the legal world as we experience: (i) a f...
Read More >
In a recent district court case out of the United States District Court for the Middle District of F...
Read More >
PE activity in Western Europe may have dipped in 2019 but this is not the full picture. Buyout activ...
Read More >
Buyers of fine art must investigate the work’s provenance before closing the deal. The same holds t...
Read More >